Weiss Ratings Reiterates Sell (D-) Rating for TScan Therapeutics (NASDAQ:TCRX)

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for TScan Therapeutics, indicating a negative outlook for the stock.
• TScan Therapeutics reported a revenue of $3.08 million for the recent quarter, significantly exceeding analysts' expectations of $1.31 million, despite strong losses.
• The company has a Moderate Buy consensus rating among analysts, with an average price target of $7.80, contrasting with Weiss Ratings' negative stance.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other research analysts have also recently issued reports about the stock. Wedbush reiterated an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. Wall Street Zen upgraded shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, TScan Therapeutics has an average rating of "Moderate Buy" and an average price target of $7.80.

TScan Therapeutics Stock Up 0.5%

Shares of TScan Therapeutics stock opened at $1.98 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.06 and a quick ratio of 7.06. TScan Therapeutics has a 1 year low of $1.02 and a 1 year high of $6.23. The firm's 50-day moving average is $1.81 and its two-hundred day moving average is $1.61. The stock has a market cap of $112.36 million, a price-to-earnings ratio of -1.82 and a beta of 0.99.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The company had revenue of $3.08 million for the quarter, compared to analysts' expectations of $1.31 million. As a group, research analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd acquired a new position in shares of TScan Therapeutics during the second quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of TScan Therapeutics during the second quarter valued at about $29,000. Quadrature Capital Ltd acquired a new position in shares of TScan Therapeutics during the second quarter valued at about $33,000. Boothbay Fund Management LLC increased its holdings in shares of TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock valued at $35,000 after acquiring an additional 8,121 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new position in shares of TScan Therapeutics during the first quarter valued at about $49,000. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.